您的位置:PharmaNews 研发动态 正文
内容搜索
热门内容
推荐内容
最新内容
反馈意见和建议

Plant Compound Resveratrol Shown to Suppress Inflammation, Free Radicals, in Humans(2)
本文章共2485字,分2页,当前第2页,快速翻页:

These inflammatory factors, in the long term, have an impact on the development of type 2 diabetes, aging, heart disease and stroke, noted Dandona.

Blood samples from the participants who received the placebo showed no change in these pro-inflammatory markers.

While these results are promising, Dandona added a caveat: The study didn't eliminate the possibility that something in the extract other than resveratrol was responsible for the anti-inflammatory effects.

"The product we used has only 20 percent resveratrol, so it is possible that something else in the preparation is responsible for the positive effects. These agents could be even more potent than resveratrol. Purer preparations now are available and we intend to test those."

Additional contributors to the study, all from Dandona's laboratory, are Chang Ling Sia, Sanaa Abuaysheh, Kelly Korzeniewski, Priyanka Patniak, MD, Anuritha Marumganti, MD, and Ajay Chaudhuri, MD.

The study was supported in part by grants to Dandona from the National Institutes of Health and the American Diabetes Association.

The University at Buffalo is a premier research-intensive public university, a flagship institution in the State University of New York system and its largest and most comprehensive campus. The School of Dental Medicine is one of five schools that constitute UB's Academic Health Center. UB's more than 28,000 students pursue their academic interests through more than 300 undergraduate, graduate and professional degree programs. Founded in 1846, the University at Buffalo is a member of the Association of American Universities.

Contact

Lois Baker

ljbaker@buffalo.edu

716-645-4606
 

 

转载自pharmaLive

 


 

 

点这里复制本页地址     发送给您QQ/MSN上的好友


相关文章

  WaferGen Announces Purchase of SmartChip

  Researchers Solve Mystery of Uner Tan Sy

  Shionogi Inc. Announces FDA Approval of

  Abraxis BioScience and Specialised Thera

  Abbott's Simcor ( niacin extended-releas

  FDA Approves Drug for Chronic Drooling i

  Quintiles Announces New European Headqua

  Covance Reports Second Quarter Revenue o

  Commonwealth Biotechnologies, Inc. Provi

New pathway to Parkinson's and Alzheimer

deCODE Shows how Genetic Risk of Kidney

Bionovo to Advance Menerba to Phase 3 Cl

Geron to Proceed with First Human Clinic

Orexigen Therapeutics Announces Publicat

Basilea Pharmaceutica AG (CH) - Data on

Study Results Show That Oral Contracepti

勃林格殷格翰糖尿病药物linagliptin一项Ⅲ期

厄洛替尼在欧盟提交申请用于具EGFR 活化突变

诺华公司肾癌治疗药物依维莫司新适应证研究

相关评论

    
本文章所属分类:首页 研发动态